<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944238</url>
  </required_header>
  <id_info>
    <org_study_id>PHY2014</org_study_id>
    <nct_id>NCT04944238</nct_id>
  </id_info>
  <brief_title>A-constant Optimization of a Toric Monofocal IOL</brief_title>
  <official_title>Optimization of the Optical Constants of the PhysIOL ANKORIS Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaver-Visitec International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beaver-Visitec International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective series study to determine the IOL constant of a hydrophilic toric&#xD;
      monofocal intra-ocular lens (IOL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective series study with he principal objective to determine the IOL&#xD;
      constant.&#xD;
&#xD;
      The secondary objectives of this study are to determine the rotational stability of the&#xD;
      Ankoris intraocular lens and to measure the residual astigmatism after Ankoris IOL&#xD;
      implantation with respect to the targeted astigmatism correction.&#xD;
&#xD;
      Although there may be no direct benefit to the subjects under study, the investigation will&#xD;
      determined the optimized constant for accurate IOL power calculation and will assess the&#xD;
      stability and efficacy of the toric optics: this would result in a benefit for the patient&#xD;
      population. Since the material, the overall design of the IOL as well as the measuring&#xD;
      procedure in this study is well tolerated in standard clinical practice and the IOL is&#xD;
      readily available and CE-marked, the benefit/risk ratio appears acceptable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2014</start_date>
  <completion_date type="Actual">June 11, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The principal objective of the study is to determine the IOL constant.</measure>
    <time_frame>1-2 hours</time_frame>
    <description>IOL constant optimisation for PCI axial length measurement of Physiol Ankoris IOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The principal objective of the study is to determine the IOL constant.</measure>
    <time_frame>1 month</time_frame>
    <description>IOL constant optimisation for PCI axial length measurement of Physiol Ankoris IOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The principal objective of the study is to determine the IOL constant.</measure>
    <time_frame>3 months</time_frame>
    <description>IOL constant optimisation for PCI axial length measurement of Physiol Ankoris IOL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rotational stability</measure>
    <time_frame>1-2 hours</time_frame>
    <description>To measure the residual astigmatism after Ankoris IOL implantation with respect to the targeted astigmatism correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational stability</measure>
    <time_frame>1 month</time_frame>
    <description>To measure the residual astigmatism after Ankoris IOL implantation with respect to the targeted astigmatism correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational stability</measure>
    <time_frame>3 months</time_frame>
    <description>To measure the residual astigmatism after Ankoris IOL implantation with respect to the targeted astigmatism correction.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Patients implanted with Ankoris IOL</arm_group_label>
    <description>To assess the IOL stability, slitlamp photos of the consecutive 30 patients with respect to time will then be analysed with a 5% confidence interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ankoris</intervention_name>
    <description>Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.</description>
    <arm_group_label>Patients implanted with Ankoris IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pseudophakic patients implanted with one of the two IOLs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient older than 50 years old&#xD;
&#xD;
          -  Age-related cataract&#xD;
&#xD;
          -  Corneal astigmatisme &gt;1 D&#xD;
&#xD;
          -  Age 21 and older&#xD;
&#xD;
          -  Visual Acuity &gt; 0.05&#xD;
&#xD;
          -  Normal findings in the medical history and physical examination unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant other ophthalmic diseases such as pseudoexfoliation syndrome, floppy iris&#xD;
             syndrome, corneal pathologies&#xD;
&#xD;
          -  Previous ocular surgery or trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Sallet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Eye Institue Aalst, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy Sallet</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

